Arcadia Biosciences (RKDA) Set to Announce Quarterly Earnings on Thursday

Arcadia Biosciences (NASDAQ:RKDAGet Rating) will issue its quarterly earnings data after the market closes on Thursday, August 11th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Arcadia Biosciences (NASDAQ:RKDAGet Rating) last posted its earnings results on Thursday, May 12th. The basic materials company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.10. The firm had revenue of $3.22 million for the quarter, compared to the consensus estimate of $1.80 million. Arcadia Biosciences had a negative net margin of 231.20% and a negative return on equity of 77.17%.

Arcadia Biosciences Price Performance

Arcadia Biosciences stock opened at $0.84 on Thursday. The company has a market capitalization of $18.67 million, a price-to-earnings ratio of -0.88 and a beta of -0.06. Arcadia Biosciences has a one year low of $0.74 and a one year high of $2.67. The company’s fifty day moving average price is $1.06 and its two-hundred day moving average price is $1.14.

Institutional Investors Weigh In On Arcadia Biosciences

A hedge fund recently raised its stake in Arcadia Biosciences stock. State Street Corp lifted its stake in Arcadia Biosciences, Inc. (NASDAQ:RKDAGet Rating) by 76.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 99,300 shares of the basic materials company’s stock after buying an additional 43,100 shares during the period. State Street Corp owned about 0.45% of Arcadia Biosciences worth $139,000 at the end of the most recent reporting period. 10.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have commented on RKDA. HC Wainwright lowered their target price on shares of Arcadia Biosciences from $6.00 to $4.00 in a research report on Monday, April 25th. StockNews.com raised shares of Arcadia Biosciences to a “sell” rating in a research report on Tuesday, May 24th.

About Arcadia Biosciences

(Get Rating)

Arcadia Biosciences, Inc produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications.

See Also

Earnings History for Arcadia Biosciences (NASDAQ:RKDA)

Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.